Beyond BCG: Tumor Board Insights on Managing Unresponsive NMIBC With Novel Treatments
Ashish Kamat, MD, MBBS; Sam Chang, MD, MBA; Bogdana Schmidt, MD, MPH; and Katie Murray, DO, MS, discuss how management of non–muscle-invasive bladder cancer (NMIBC) requires careful risk stratification, standardized BCG therapy protocols, consideration of alternative treatments for BCG-unresponsive disease, gender-specific approaches, and specialized care for younger patients to improve outcomes and quality of life.
EP. 1: Non–Muscle Invasive-Bladder Cancer Overview
May 16th 2025Panelists discuss how non–muscle-invasive bladder cancer (NMIBC) is staged, graded, and treated according to risk stratification, with detailed explanations of low-, intermediate-, and high-risk categories and corresponding treatment pathways.
EP. 2: Case 1: A 79-Year-Old Man With Non–Muscle-Invasive Bladder Cancer
May 23rd 2025Panelists discuss how they approach a typical bladder cancer case of a 79-year-old man with hematuria, including initial diagnostic procedures, the importance of proper tumor measurement during resection, BCG therapy protocols, and management options for BCG-unresponsive disease with a focus on nadofaragene firadenovec (Adstiladrin).
EP. 3: Case 2: A 68-Year-Old Woman With Non–Muscle-Invasive Bladder Cancer
June 2nd 2025Panelists discuss how to manage the treatment of a 68-year-old woman with painless intermittent hematuria and positive cytology for high-grade urothelial cancer, addressing gender differences in diagnosis timing, the importance of repeat transurethral resection (TURBT) procedures, BCG therapy options, and considerations for radical cystectomy with pelvic organ preservation when BCG fails.
